Program
CDK4 Inhibitor BGB-43395
Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis, led by BeOne Medicines.
Furthest: phase 3, since Mar 20, 20264 company-led studies, 2 open or runningNext primary completion: Nov 22, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeOne Medicines | 42 open or running | phase 3since Mar 20, 2026 | Feb 2, 2024 | Nov 22, 2026phase 1 · NCT07820891 |
Also a collaborator on its studies: Fortrea.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 2, 2024First study: phase 1 study in Neoplasm MetastasisFirst studyNCT06253195 · 33 enrolled · China
- Dec 31, 2024Phase 1 study in Healthy VolunteersNCT06761898 · 51 enrolled · United States
- Mar 20, 2026Phase 3 study in HR+/HER2- Breast CancerPhase 3 reachedNCT07492641 · 1,056 planned · United States, Australia, Brazil and more
- Sep 10, 2026Phase 1 study in Healthy Adult ParticipantsNCT07820891 · 24 planned · United States
Ahead
- Nov 22, 2026Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07820891
- Apr 2029Primary completion: phase 3 study in HR+/HER2- Breast CancerNCT07492641
TargetBeta
CDK4 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinase 4 (CDK4), ”NCIt, by rule
Other programs on CDK4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abemaciclibrule | Eli Lilly | phase 4 | 49 |
| palbociclibrule | Pfizer | phase 4 | 36 |
| trilaciclibrule | Pharmacosmos | phase 4 | 14 |
| atirmociclib | Pfizer | phase 3 | 17 |
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| HRS-6209 | Jiangsu HengRui Medicine | phase 3 | 7 |
| narazaciclibrule | hangzhou-hanx-biopharmaceuticals-ltd | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| TSL2109rule | China Resources Pharmaceutical Group | phase 1 | 1 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07820891Healthy Adult Participants · United States | 1 | Recruiting | Nov 22, 2026 | 24 |
| NCT07492641HR+/HER2- Breast Cancer · United States, Australia, Brazil and more | 3 | Recruiting | Apr 2029 | 1,056 |
| NCT06761898Healthy Volunteers · United States | 1 | Completed | May 20, 2025 | 51 |
| NCT06253195Neoplasm Metastasis · China | 1 | Completed | Apr 23, 2026 | 33 |
How it is read
Names in the registry
- “BGB-43395”, 5 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.